key: cord-0764032-gw2fvv0t
authors: O’Callaghan, M.E.; Jay, A.; Kichenadasse, G.; Moretti, K.L.
title: Androgen Deprivation Therapy in Unlikely to be Effective for Treatment of COVID-19
date: 2020-09-30
journal: Ann Oncol
DOI: 10.1016/j.annonc.2020.09.014
sha: 317539001774742eff919e064e55756b7a0eaa41
doc_id: 764032
cord_uid: gw2fvv0t

nan

Recent literature has reported that patients with prostate cancer treated with androgen deprivation 27 therapy (ADT) have a lower incidence of SARS-COV-2, an observation which has been widely 28 reported by media outlets, together with speculation that ADT may be a potential treatment for 29 COVID-19. The study by Montopoli et al was conducted at a population level in Italy, a region 30 experiencing a high level of COVID-19 cases. [1] They observed in a cohort of men with prostate 31 cancer that those prescribed ADT were less likely to report COVID-19 (4/5273 cases vs 114/37161, 32 OR 4.05, 95% CI 1.55-10.59, p=0.00043). Benefits were also observed for classification of mild and 33 severe disease and were used as a basis of the conclusion that "ADT, based on luteinizing hormone-34 releasing hormone (LHRH) agonist/antagonists or AR inhibitors, may be considered to reduce SARS-35

A useful metric to consider in this context is the number needed to treat, which is calculable from 37 the data reported, but was not included by Montopoli transiently to minimise adverse events, though this hypothesis has not been tested in the data they 44 present. Transient ADT treatment may be appropriate to reduce complications in those already 45 infected with SARS-COV-2, although ADT adverse events are typically most common immediately 46 after commencement [3] . 47

The mechanism of action which Montopoli et al describe may provide a novel target for COVID-19 48 treatments, but it seems unlikely that existing ADTs will provide a viable treatment option. 49 

Pagano 64 F, Ragazzi. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a 65 population-based study (n= 4532)

Adverse effects of androgen deprivation 69 therapy in prostate cancer: Current management issues. Indian journal of urology : IJU : journal of 70 the Urological Society of India

Risk and timing 73 of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer